Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania

Behavioural Brain Research

Volumn 158, Issue 1, 2005, Pages 123-132

  Arban, Roberto ^a   Maraia, Gabriella ^a   Brackenborough, Kim ^b   Winyard, Lisa ^b   Wilson, Alex ^b   Gerrard, Philip ^a   Large, Charles ^a  

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Animal model; Anticonvulsant; Bipolar disorder; Hyperactivity; Seizure

Indexed keywords

CARBAMAZEPINE; CHLORDIAZEPOXIDE; DEXAMPHETAMINE; GLUTAMIC ACID; LAMOTRIGINE; PENTETRAZOLE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG TOLERABILITY; EXPERIMENTAL MODEL; GABAERGIC SYSTEM; HYPERACTIVITY; LOCOMOTION; LOW DRUG DOSE; MALE; MANIA; MENTAL INSTABILITY; MOUSE; NERVE CELL EXCITABILITY; NEUROTRANSMISSION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN SECRETION; RODENT; SEDATION; STATISTICAL SIGNIFICANCE; TONIC CLONIC SEIZURE; VALIDATION PROCESS;

ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; BIPOLAR DISORDER; CARBAMAZEPINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHLORDIAZEPOXIDE; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; MICE; MOTOR ACTIVITY; PENTYLENETETRAZOLE; PSYCHOMOTOR AGITATION; SEIZURES; TRIAZINES; VALPROIC ACID;

EID: 12944298271     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2004.08.015     Document Type: Article

References (70)

1. R.M. Post, S.R. Weiss, M. Smith, J. Rosen, and M. Frye Stress, conditioning and the temporal aspects of affective disorders Ann N Y Acad Sci 771 1995 677 696
2. M. Elphick The clinical uses and pharmacology of carbamazepine in psychiatry Int Clin Psychopharmacol 3 1988 185 203
3. C. Lennkh, and C. Simhandl Current aspects of valproate in bipolar disorder Int Clin Psychopharmacol 15 2000 1 11
4. O.A. De Leon Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder Harvard Rev Psych 9 2001 209 222
5. S.L. McElroy, and P.E. Keck Jr. Pharmacologic agents for the treatment of acute bipolar mania Biol Psychiatry 48 2000 539 557
6. P.E. Keck, S.L. McElroy, N. Richtand, and M. Tohen What makes a drug a primary mood stabiliser? Mol Psych 7 2002 S8 S14
7. J.A. Messenheimer Lamotrigine Epilepsia 36 1995 87 94
8. C.L. Bowden Novel treatments for bipolar disorder Expert Opin Investig Drugs 10 2001 661 671
9. S.H. Fatemi, D.J. Rapport, J.R. Calabrese, and P. Thuras Lamotrigine in rapid-cycling bipolar disorder J Clin Psychiatry 58 1997 522 527
10. R.M. Hamer, and P.M. Simpson The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder Biol Psychiatry 46 1999 1711 1712
11. C.L. Bowden, J.R. Calabrese, S.L. McElroy, L.J. Rhodes, P.E. Keck Jr., and J. Cookson The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder Biol Psychiatry 45 1999 953 958
12. J.R. Calabrese, C.L. Bowden, S.L. McElroy, J. Cookson, J. Andersen, and P.E. Keck Jr. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder Am J Psychiatry 156 1999 1019 1023
13. J.R. Calabrese, C.L. Bowden, G.S. Sachs, J.A. Ascher, E. Monaghan, and G.D. Rudd A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression J Clin Psychiatry 60 1999 79 88
14. L. Ichim, M. Berk, and S. Brook Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial Ann Clin Psychiatry 12 2000 5 10
15. T.A. Ketter, H.K. Manji, and R.M. Post Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders J Clin Psychopharm 23 2003 484 495
16. R.M. Post, T.A. Ketter, K. Denicoff, P.J. Pazzaglia, G.S. Leverich, and L.B. Marangell The place of anticonvulsant therapy in bipolar illness Psychopharmacology 128 1996 115 129
17. W. Loscher Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action Prog Neurobiol 58 1999 31 59
18. L.M. Frank, T. Enlow, G.L. Holmes, P. Manasco, S. Concannon, C. Chen, G. Womble, and E.J. Casale Lamictal (lamotrigine) monotherapy for typical absence seizures in children Epilepsia 140 1999 973 979
19. A.P. Parker, A. Agathonikou, R.O. Robinson, and C.P. Panayiotopoulos Inappropriate use of carbamazepine and vigabatrin in typical absence seizures Dev Med Child Neurol 40 1998 517 519
20. R. Rushton, and H. Steinberg Combined effects of chlordiazepoxide and d-amphetamine on activity of rats in an unfamiliar environment Nature 211 1966 1312 1313
21. C.G. Aylmer, H. Steinberg, and R.A. Webster Hyperactivity induced by dexd-amphetamine/chlordiazepoxide mixtures in rats and its attenuation by lithium pretreatment: a role for dopamine? Psychopharmacology 91 1987 198 206
22. A.L. Vale, and F. Ratcliffe Effect of lithium administration on rat brain 5-hydroxyindole levels in a possible model for mania Psychopharm 91 1987 352 355
23. B.-J. Cao, and N.-A. Peng Magnesium valproate attenuates hyperactivity induced by dexd-amphetamine-chlordiazepoxide mixture in rodents Eur J Pharmacol 237 1993 177 181
24. K.A. Serpa, and L.T. Meltzer Chlordiazepoxide/d-amphetamine induced hyperactivity in rats: assessment as mania model using automated activity chambers Soc Neurosci Abstr 25 1999 533 613
25. Y. Lamberty, D.G. Margineau, and H. Klitgaard Effect of the new antiepileptic drug levetiracetam in an animal model of mania Epilepsy Behav 2 2001 454 459
26. L.H. Conti, D.S. Segal, and R. Kuczenski Maintenance of d-amphetamine-induced stereotypy and locomotion requires ongoing dopamine receptor activation Psychopharmacology (Berlin) 130 1997 183 188
27. R.S. Fisher Animal models of the epilepsies Brain Res Rev 14 1989 245 278
28. T.A. Ketter, and J.R. Calabrese Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature J Clin Psychiatry 63 2002 146 151
29. P.W.P. Butler, G.M. Besser, and H. Steinberg Changes in plasma cortisol induced by dexd-amphetamine and chlordiazepoxide given alone and in combination in man J Endocr 40 1967 391 392
30. G.M. Besser, and H. Steinberg The interaction of chlordiazepoxide and d-amphetamine in man Thérapie 22 1967 977
31. L.N. Yatham Prolactin and cortisol responses to fenfluramine challenge in mania Biol Psych 39 1996 285 288
32. R. Yehuda, D. Boisoneau, J.W. Mason, and E.L. Giller Glucocorticoid receptor number and cortisol excretion in mood, anxiety, and psychotic disorders Biol. Psych 34 1993 18 25
33. P. Linkowski, M. Kerkhofs, A. Van Onderbergen, P. Hubain, G. Copinschi, and M. L'Hermite-Baleriaux The 24-hour profiles of cortisol, prolactin, and growth hormone secretion in mania Arch Gen Psychiatry 51 1994 616 624
34. C.U. Johannessen Mechanism of action of valproate: a commentary Neurochem Int 37 2000 103 110
35. H. Ashton, and A.H. Young GABA-ergic drugs: exit stage left, enter stage right J Psychopharmacol 17 2003 174 178
36. T.A. Ketter, and P.W. Wang The emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders J Clin Psychiatry 64 Suppl. 3 2003 15 20
37. M.C. Walker The mechanism of action of tiagabine Rev Contemp Pharmacother 12 2002 213 223
38. A.E. Evins Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders J Clin Psychiatry 64 Suppl. 8 2003 9 14
39. M.O. Cunningham, and R.S.G. Jones The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro Neuropharm 39 2000 2139 2146
40. B. Hassel, E. Tauboll, and L. Gjerstad Chronic lamotrigine treatment increases rat hippocampal GABA shunt activity and elevates cerebral taurine levels Epilepsy Res 43 2001 153 163
41. R. Kuzniecky, S. Ho, J. Pan, R. Martin, F. Gilliam, and E. Faught Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults Neurology 58 2002 368 372
42. S.A. Brody, M.A. Geyer, and C.H. Large Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice Psychopharmacology 169 2003 240 246
43. Idris N, Neill J, Large CH. Lamotrigine reverses disruption of the serial reversal task by PCP in rats. Psychopharmacology (submitted).
44. J.H. Krystal, D.C. D'Souza, D. Mathalon, E. Perry, A. Belger, and R. Hoffman NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development Psychopharm 169 2003 215 233
45. B. Moghaddam, B. Adams, A. Verma, and D. Daly Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with prefrontal cortex J Neurosci 17 1997 2921 2927
46. S.-J. Wang, C.-C. Huang, K.-S. Hsu, J.-J. Tsai, and P.-W. Gean Presynaptic inhibition of excitatory neurotransmission by lamotrigine in rat amygdalar neurons Synapse 24 1996 248 255
47. P. Calabresi, D. Centonze, G.A. Marfia, A. Pisani, and G. Bernardi An in vitro electrophysiological study of the effects of phenytoin, lamotrigine and gabapentin on striatal neurons Br J Pharmacol 126 1999 689 696
48. + channels in rat hippocampal neurones Eur J Pharm 430 1995 437 446
49. X. Xie, and R.M. Hagan Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder Neuropsychobiology 38 1998 119 130
50. R.A. Cunha, J.E. Coelho, A.R. Costenla, L.V. Lopes, A. Parada, and A. de Mendonça Effects of carbamazepine and novel 10,11-dihydro-5H-dibenz[b f]azepine-5-carboxamide derivatives on synaptic transmission in rat hippocampal slices Pharmacol Toxicol 90 2002 208 213
51. P.C. Waldmeier, P.A. Baumann, P. Wicki, J.-J. Feldtrauer, C. Stierlin, and M. Schmutz Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters Neurology 45 1995 1907 1913
52. M. Willow, T. Gonoi, and W.A. Catterall Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells Mol Pharmacol 27 1995 549 558
53. + channels Mol. Pharm. 54 1998 712 721
54. 2+ levels in neuronal culture Eur J Pharmacol 219 1992 53 57
55. J.M. Lancaster, and J.A. Davies Carbamazepine inhibits NMDA-induced depolarizations in cortical wedges prepared from DBA/2 mice Experientia 48 1992 751 753
56. C.J. Hough, R.P. Irwin, X.M. Gao, M.A. Rogawski, and D.M. Chuang Carbamazepine inhibition of N-methyl-d-aspartate-evoked calcium influx in rat cerebellar granule cells J Pharmacol Exp Ther 276 1996 143 149
57. 2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists Neuropharmacology 38 1999 1349 1359
58. R. Gillham, K. Kane, L. Bryant-Comstock, and M.J. Brodie A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure Seizure 9 2000 375 379
59. J.F. Dixon, and L.E. Hokin The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4,5-trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and bisphosphates Proc Natl Acad Sci USA 94 1997 4757 4760
60. Y. Ueda, and L.J. Willmore Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis Exp Brain Res 133 2000 334 339
61. J.W. Olney, J.W. Newcomer, and N.B. Farber NMDA receptor hypofunction model of schizophrenia J Psychiatric Res 33 1999 523 533
62. + channels: an unexpected form of cellular plasticity. Nat Rev (Neurosci) 2 2001 397 407
63. D.A. Hosford, F.H. Lin, Y. Wang, S.J. Caddick, M. Rees, and N.J. Parkinson Studies of the lethargic (lh/lh) mouse model of absence seizures: regulatory mechanisms and identification of the lh gene Adv Neurol 79 1999 239 252
64. D.A. Coulter Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in? J Child Neurol 12 1997 S2 S9
65. S.M. Dursun, and D. McIntosh Clozapine plus lamotrigine in treatment-resistant schizophrenia (letter) Arch Gen Psychiatry 56 1999 950
66. J. Tiihonen, T. Hallikainen, O.P. Ryynanen, E. Repo-Tiihonen, I. Kotilainen, and M. Eronen Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial Biol Psychiatry 54 2003 1241 1248
67. G.N. Ko, E.R. Korpi, W.J. Freed, S.J. Zalcman, and L.B. Bigelow Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenic patients Biol Psychiatry 20 1985 199 228
68. W.T. Carpenter, R. Kurz, B. Kirkpatrick, T.E. Hanlon, A.T. Summerfelt, and R.W. Buchanan Carbamazepine maintenance treatment in outpatient schizophrenics Arch Gen Psychiatry 48 1991 69 72
69. M. Dose, R. Hellweg, A. Yassouridis, M. Theison, and H.M. Emrich Combined treatment of schizophrenic psychoses with haloperidol and valproate Pharmacopsychiatry 31 1998 122 125
70. B. Hesslinger, C. Normann, J.M. Langosch, P. Klose, M. Berger, and J. Walden Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients J Clin Psychopharmacol 19 1999 310 315